Traws Pharma, Inc. (NASDAQ:TRAW) Given Average Recommendation of “Hold” by Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have earned a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $8.00.

TRAW has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Citigroup downgraded shares of Traws Pharma to a “neutral” rating in a research report on Monday. Wall Street Zen upgraded shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Traws Pharma in a research note on Wednesday, May 20th.

Insider Activity at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc acquired 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was acquired at an average cost of $1.67 per share, with a total value of $998,207.43. Following the purchase, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.57% of the stock is owned by insiders.

Hedge Funds Weigh In On Traws Pharma

A number of large investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. boosted its stake in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Squadron Capital Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth about $806,000. Ikarian Capital LLC boosted its stake in shares of Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth about $220,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth about $175,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

Traws Pharma Stock Performance

Shares of Traws Pharma stock opened at $1.28 on Monday. Traws Pharma has a one year low of $1.00 and a one year high of $3.27. The stock’s fifty day moving average is $1.49 and its 200 day moving average is $1.74. The stock has a market cap of $13.00 million, a P/E ratio of -0.76 and a beta of 1.45.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.39. Analysts predict that Traws Pharma will post -2.23 EPS for the current year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.